Showing 1821-1830 of 2727 results for "".
- Cynosure Receives $60 Million Follow-on Investment from Clayton, Dubilier & Ricehttps://modernaesthetics.com/news/cynosure-recieves-60-million-follow-on-investment-from-clayton-dubilier-rice/2473237/Cynosure, LLC, received $60 million from lead investor Clayton, Dubilier & Rice. The new capital supports the company's plans to continue investing ahead of strong growth to bring innovation to the market and provide comprehensive treatment solutions to its cust
- ISHRS Survey: Surgical Advances; Improvements in Efficiency Driving Need for Fewer Hair Transplant Treatmentshttps://modernaesthetics.com/news/ishrs-survey-surgical-advances-improvements-in-efficiency-driving-need-for-fewer-hair-transplant-treatments/2473235/According to results of a new member survey conducted by the International Society of Hair Restoration Surgery (ISHRS), 68 percent of members reported performing an average of one procedure per patient in 2021 to achieve the desired hair restoration result. This represents a significant improveme
- CellFX from Pulse Biosciences Shows Durable Effects for Sebaceous Hyperplasia: ASLMS Presentationhttps://modernaesthetics.com/news/cellfx-from-pulse-biosciences-shows-durable-effects-for-sebaceous-hyperplasia-aslms-presentation/2473233/The CellFX® system from Pulse Biosciences, Inc. demonstrates durable efficacy for the clearance of Sebaceous Hyperplasia lesions, according to data presented at the 2022
- R2 Technologies Ships 100 GLACIAL Deviceshttps://modernaesthetics.com/news/r2-technologies-ships-100-glacial-devices/2473224/R2 Technologies Inc. has shipped 100 GLACIAL Rx devices across the globe. To-date customers have delivered more than 15,000 GLACIAL treatment cycles, helping patients reach their skin goals by reducing inflammation and revealing younger looking skin. R2 reached this mileston
- Revance News: FDA Accepts BLA Resubmission for DaxibotulinumtoxinAhttps://modernaesthetics.com/news/revance-news-fda-accepts-bla-resubmission-for-daxibotulinumtoxina/2473223/The U.S. Food and Drug Administration (FDA) accepted Revance’s Biologics License Application (BLA) resubmission for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines. The FDA designated the BLA as a Class 2 resubmission, which has a six-mont
- Jeune Aesthetics Shares Positive Clinical Phase 1 Data for Investigational Gene-based Treatment to Address the Underlying Biology of Aging Skinhttps://modernaesthetics.com/news/jeune-aesthetics-shares-positive-clinical-phase-1-data-for-investigational-gene-based-treatment-to-address-the-underlying-biology-of-aging-skin/2473210/Jeune Aesthetics, Inc., a wholly-owned subsidiary of Krystal Biotech, Inc. shared positive proof-of-concept efficacy data from Cohort 2 of its PEARL-1 study of KB301, Jeune Aesthetics’ lead candidate for the treatment of aesthetic skin conditions. “We are pleased to see
- This National Peel Day, PCA Skin Asks, #HowYouPeelinhttps://modernaesthetics.com/news/this-national-peel-day-pca-skin-asks-howyoupeelin/2473206/PCA SKIN® wants to know #HowYouPeelin, as the company celebrates the third annual National Peel Day, Thursday, highlighting their latest peel innovation, new partnership, special promotion for accounts, and a host of social media activities. National Peel Day is recognize
- The Beauty Health Company Introduces HydraFacial Syndeo Delivery Systemhttps://modernaesthetics.com/news/the-beauty-health-company-introduces-hydrafacial-syndeo-delivery-system/2473205/The Beauty Health Company is rolling out the HydraFacial Syndeo, a digital device that aims to enhance the consumer and provider experience. “As a category creator, we deliver beauty health experiences every day that re-invent our consumer’s relationship with their ski
- Revance Resubmits BLA for DaxibotulinumtoxinAhttps://modernaesthetics.com/news/revance-resubmits-bla-for-daxibotulinumtoxina/2473204/Revance Therapeutics, Inc. has resubmitted its Biologics License Application (BLA) to FDA for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines. The submission is in response to the Complete Response Letter (CRL) issued by FDA in October 2021. The
- Hallura’s New BiOLinkMatrix HA Aesthetic Dermal Fillers Perform Well in Lips, Cheeks, and Smile Lineshttps://modernaesthetics.com/news/halluras-new-biolinkmatrix-ha-aesthetic-dermal-fillers-performs-well-in-lips-cheeks-and-smile-lines/2473203/Hallura Ltd’s hyaluronic acid (HA) dermal fillers with its proprietary BiOLinkMatrix platform performed well for lip enhancement, nasolabial folds correction. and cheek enhancement, according to topline results. The pro